AR065640A1 - Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma - Google Patents
Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la mismaInfo
- Publication number
- AR065640A1 AR065640A1 ARP080100948A ARP080100948A AR065640A1 AR 065640 A1 AR065640 A1 AR 065640A1 AR P080100948 A ARP080100948 A AR P080100948A AR P080100948 A ARP080100948 A AR P080100948A AR 065640 A1 AR065640 A1 AR 065640A1
- Authority
- AR
- Argentina
- Prior art keywords
- lyophilized preparation
- preparation
- iii
- influenza vaccine
- liofilized
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 229960003971 influenza vaccine Drugs 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 229940024606 amino acid Drugs 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un preparado liofilizado en el cual la vacuna contra la influenza presenta una estabilidad mejorada. Un preparado liofilizado en el cual la vacuna contra la influenza presenta estabilidad significativamente mejorada puede ser obtenido liofilizandouna solucion acuosa que cumple con las siguientes condiciones (A) a (C) en la preparacion de un preparado liofilizado que contiene una vacuna contra la influenza: (A) se incorporan (i) una vacuna contra la influenza, (ii) un aminoácido hidrofobo y(iii) arginina y una sal de adicion de acido de la misma: (B) la proporcion del componente (iii) es de 20 a 85% en peso con relacion a la cantidad total del preparado liofilizado resultante; y (C) el pH es ajustado para ser de 8 a 10 controlando laproporcion de arginia y una sal de adicion de acido de la misma que forma el componente (iii). Reivindicacion 3: un preparado liofilizado de acuerdo con la reivindicacion 1, caracterizado porque el (ii) aminoácido hibrofobo es fenilalanina, o unacombinacion de fenilalanina con por lo menos uno de valina, leucina e isoleucina. Reivindicacion 9: un preparado liofilizado de acuerdo con la reivindicacion 1, que es un preparado farmaceutico para la administracion transpulmonar. Reivindicacion10: un preparado liofilizado de acuerdo con la reivindicacion 1, que es en preparado farmaceutico para la administracion nasal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007059724 | 2007-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065640A1 true AR065640A1 (es) | 2009-06-17 |
Family
ID=39759470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100948A AR065640A1 (es) | 2007-03-09 | 2008-03-07 | Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8216588B2 (es) |
| EP (1) | EP2119451A4 (es) |
| JP (1) | JP5388842B2 (es) |
| KR (1) | KR20090128463A (es) |
| CN (1) | CN101631563B (es) |
| AR (1) | AR065640A1 (es) |
| AU (1) | AU2008225501B2 (es) |
| BR (1) | BRPI0808037A2 (es) |
| CA (1) | CA2680193C (es) |
| HK (1) | HK1139076A1 (es) |
| IL (1) | IL200588A0 (es) |
| MX (1) | MX2009009635A (es) |
| MY (1) | MY149924A (es) |
| NZ (1) | NZ579395A (es) |
| RU (1) | RU2484847C2 (es) |
| SG (1) | SG179406A1 (es) |
| TW (1) | TWI428140B (es) |
| UA (1) | UA97391C2 (es) |
| WO (1) | WO2008111532A1 (es) |
| ZA (1) | ZA200905952B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0614460D0 (en) * | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| CN103620025A (zh) * | 2011-06-28 | 2014-03-05 | 白血球保健股份有限公司 | 病毒或细菌的新型稳定方法 |
| PL2948129T3 (pl) * | 2013-01-25 | 2018-05-30 | Wintermute Biomedical, Inc. | Związki terapeutyczne |
| GB201314248D0 (en) * | 2013-08-08 | 2013-09-25 | Glaxosmithkline Biolog Sa | Saccharide vaccine formulation |
| EP3041504B1 (en) * | 2013-09-03 | 2021-08-25 | Georgia Tech Research Corporation | Thermally stable vaccine formulations and microneedles |
| EP3060247A1 (en) * | 2013-10-25 | 2016-08-31 | Leukocare Ag | A novel method for the production of stabile vaccines |
| WO2017090766A1 (ja) | 2015-11-27 | 2017-06-01 | 日東電工株式会社 | 口腔内投与用ワクチン医薬組成物及び口腔内投与用ワクチン医薬組成物の製造方法 |
| TW201722478A (zh) * | 2015-11-27 | 2017-07-01 | Nitto Denko Corp | 流感疫苗乾燥製劑、及流感疫苗乾燥製劑之製造方法 |
| TW201720426A (zh) * | 2015-11-27 | 2017-06-16 | Nitto Denko Corp | 流感疫苗乾燥製劑、及流感疫苗乾燥製劑之製造方法 |
| US11065220B2 (en) | 2017-02-13 | 2021-07-20 | Wintermute Biomedical, Inc. | Anti-pathogenic therapeutic compositions |
| WO2020072479A1 (en) | 2018-10-01 | 2020-04-09 | Wintermute Biomedical, Inc. | Therapeutic compositions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| US4537769A (en) | 1982-04-06 | 1985-08-27 | American Cyanamid Company | Stabilization of influenza virus vaccine |
| JPH07121871B2 (ja) * | 1986-10-09 | 1995-12-25 | 国立予防衛生研究所長 | インフルエンザワクチン凍結乾燥製剤 |
| JPH05229960A (ja) * | 1990-10-30 | 1993-09-07 | Dai Ichi Seiyaku Co Ltd | 新規インフルエンザワクチン |
| JPH0813753B2 (ja) * | 1992-05-22 | 1996-02-14 | 株式会社微生物化学研究所 | 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ３型ウイルス感染症、牛ｒｓウイルス感染症および牛アデノ７型ウイルス感染症５種混合生ワクチン |
| AU2001244584B2 (en) * | 2000-03-31 | 2006-01-19 | Kirin Pharma Kabushiki Kaisha | Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability |
| EG24184A (en) * | 2001-06-15 | 2008-10-08 | Otsuka Pharma Co Ltd | Dry powder inhalation system for transpulmonary |
| JP2004054555A (ja) * | 2002-07-19 | 2004-02-19 | Yokogawa Electric Corp | 表示装置 |
| CN101804202B (zh) | 2003-02-25 | 2014-06-18 | 米迪缪尼有限公司 | 制备流感疫苗组合物的方法 |
| KR101346989B1 (ko) * | 2004-10-06 | 2014-02-06 | 메디뮨 엘엘씨 | 냉장 온도 안정성 인플루엔자 백신 조성물 |
| RU2290205C1 (ru) * | 2005-09-13 | 2006-12-27 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунологическим препаратам "МИКРОГЕН" Министерства здравоохранения Российской Федерации | Способ получения живой вакцины для профилактики гриппа |
-
2008
- 2008-03-07 TW TW097108118A patent/TWI428140B/zh not_active IP Right Cessation
- 2008-03-07 WO PCT/JP2008/054210 patent/WO2008111532A1/ja active Application Filing
- 2008-03-07 UA UAA200910179A patent/UA97391C2/ru unknown
- 2008-03-07 JP JP2009504039A patent/JP5388842B2/ja not_active Expired - Fee Related
- 2008-03-07 MX MX2009009635A patent/MX2009009635A/es active IP Right Grant
- 2008-03-07 CN CN2008800077114A patent/CN101631563B/zh not_active Expired - Fee Related
- 2008-03-07 MY MYPI20093554A patent/MY149924A/en unknown
- 2008-03-07 EP EP08721627A patent/EP2119451A4/en not_active Withdrawn
- 2008-03-07 US US12/529,893 patent/US8216588B2/en not_active Expired - Fee Related
- 2008-03-07 AR ARP080100948A patent/AR065640A1/es unknown
- 2008-03-07 KR KR1020097020993A patent/KR20090128463A/ko active IP Right Grant
- 2008-03-07 BR BRPI0808037-2A2A patent/BRPI0808037A2/pt not_active IP Right Cessation
- 2008-03-07 AU AU2008225501A patent/AU2008225501B2/en not_active Ceased
- 2008-03-07 NZ NZ579395A patent/NZ579395A/en not_active IP Right Cessation
- 2008-03-07 CA CA2680193A patent/CA2680193C/en not_active Expired - Fee Related
- 2008-03-07 SG SG2012012985A patent/SG179406A1/en unknown
- 2008-03-07 RU RU2009137380/15A patent/RU2484847C2/ru not_active IP Right Cessation
-
2009
- 2009-08-26 IL IL200588A patent/IL200588A0/en unknown
- 2009-08-27 ZA ZA2009/05952A patent/ZA200905952B/en unknown
-
2010
- 2010-06-10 HK HK10105830.1A patent/HK1139076A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090128463A (ko) | 2009-12-15 |
| CN101631563B (zh) | 2013-07-24 |
| RU2009137380A (ru) | 2011-04-20 |
| HK1139076A1 (en) | 2010-09-10 |
| ZA200905952B (en) | 2010-11-24 |
| WO2008111532A1 (ja) | 2008-09-18 |
| US8216588B2 (en) | 2012-07-10 |
| AU2008225501A2 (en) | 2009-09-24 |
| AU2008225501B2 (en) | 2013-08-29 |
| AU2008225501A1 (en) | 2008-09-18 |
| CN101631563A (zh) | 2010-01-20 |
| IL200588A0 (en) | 2010-05-17 |
| MY149924A (en) | 2013-10-31 |
| MX2009009635A (es) | 2009-09-22 |
| EP2119451A4 (en) | 2012-05-16 |
| TW200848074A (en) | 2008-12-16 |
| JPWO2008111532A1 (ja) | 2010-06-24 |
| EP2119451A1 (en) | 2009-11-18 |
| TWI428140B (zh) | 2014-03-01 |
| CA2680193C (en) | 2015-05-05 |
| JP5388842B2 (ja) | 2014-01-15 |
| UA97391C2 (ru) | 2012-02-10 |
| NZ579395A (en) | 2012-05-25 |
| BRPI0808037A2 (pt) | 2014-06-17 |
| CA2680193A1 (en) | 2008-09-18 |
| SG179406A1 (en) | 2012-04-27 |
| RU2484847C2 (ru) | 2013-06-20 |
| US20100104595A1 (en) | 2010-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065640A1 (es) | Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma | |
| HRP20201948T1 (hr) | Pripravci inhibitora dopa-dekarbokilaze | |
| BR112014011162A2 (pt) | derivados purínicos para o tratamento de infecções virais | |
| JP2017533218A5 (es) | ||
| BR112013022495A2 (pt) | formulação farmacêutica aquosa de tapentadol para administração oral | |
| PE20121517A1 (es) | Compuestos lipopeptidos y metodos relacionados | |
| BR112014019667A2 (pt) | formulação de anticorpo abeta | |
| BR112014006897A2 (pt) | sistema de cabeça de fraturamento ajustável e câmara tubular | |
| BR112015000615A2 (pt) | purinas macrocíclicas para o tratamento de infecções virais | |
| AR077225A1 (es) | Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza | |
| GT201400027A (es) | Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina | |
| AR083366A1 (es) | Formulaciones para el tratamiento de las afecciones de las vias aereas superiores | |
| PE20171178A1 (es) | Composicion de rehidratacion oral y los metodos de la misma | |
| MX348831B (es) | Administración parenteral de tapentadol. | |
| UA117480C2 (uk) | Лікування цукрового діабету за допомогою складу інсуліну тривалої дії | |
| CL2013003057A1 (es) | Composicion farmaceutica de aerosol en forma de solución acuosa para nebulización que comprende iloprost, que proporciona una dosis unica eficaz aerolizada para inhalacion de bolo en un periodo de menos de 2 minutos; kit farmacéutio, util en el tratamiento de hipertension arterial pulmonar. | |
| PE20130728A1 (es) | Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| BR112022002582A2 (pt) | Sais de peptídeo hidrofóbicos para composições de liberação prolongada | |
| AR096854A1 (es) | Composición farmacéutica para una liberación sostenida de lanreotide | |
| BR112014009242A2 (pt) | nanossuspensão farmacêutica | |
| UY35771A (es) | Tienouracil-carboxamidas cíclicas y su uso | |
| PE20130374A1 (es) | Composicion farmaceutica que comprende ibuprofeno | |
| BR112013024801A2 (pt) | formulações de otamixaban com estabilidade aprimorada | |
| ECSP11010856A (es) | Composición farmacéutica sólida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |